Sign in

Dave Risinger

Senior Managing Director and Senior Research Analyst at Leerink Partners

Dave Risinger is a Senior Managing Director and Senior Research Analyst at Leerink Partners, specializing in diversified biopharmaceuticals and healthcare equity research. He covers a broad portfolio of companies including Johnson & Johnson, Alkermes, Bausch Health, and a total of up to 32 stocks primarily in the medical and large-cap pharmaceutical sectors, with a track record of over 66% success rate and an average return of 14.6% on stock recommendations. Risinger began his Wall Street career at Dillon, Read & Co. and subsequently held senior roles at Merrill Lynch, where he was head of Global Healthcare Research, and Morgan Stanley, where he led U.S. Major and Specialty Pharmaceuticals Equity Research before joining Leerink Partners in 2022. He holds the Chartered Financial Analyst (CFA) designation, has a BA in Political Science from Bucknell University, and has been recognized by Institutional Investor with top analyst rankings and runner-up honors in major pharmaceutical categories.

Dave Risinger's questions to AbbVie (ABBV) leadership

Question · Q3 2025

Dave Risinger asked about the outlook for accelerating growth as Humira's absolute dollar declines diminish in coming years and requested an overview of the top pipeline candidate readouts expected over the next six months, including Amylin.

Answer

EVP and CFO Scott Reents affirmed confidence in achieving high single-digit growth through the decade as Humira's absolute dollar decline lessens, expecting earnings growth to outpace revenue. EVP, Research and Development, and CSO Roopal Thakkar outlined upcoming readouts in immunology (SKYRIZI combinations, lutikizumab), oncology (TMAB-A, Tantamig, 151, bispecific ADC), neuroscience (VRAYLAR follow-on, imuracladine), and obesity (Amylin Phase 1 and 1B data).

Ask follow-up questions

Question · Q3 2025

Dave Risinger asked about the outlook for accelerating growth as HUMIRA's absolute dollar declines diminish and requested an update on the top pipeline candidate readouts expected over the next six months, including amylin.

Answer

Scott Reents, Executive Vice President, Chief Financial Officer, explained that HUMIRA's absolute dollar decline will diminish, supporting the long-term guidance of high single-digit growth through the decade, with operating margin expansion driving faster earnings growth. Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, outlined key pipeline readouts for 2026, including IBD combination data, oncology data, neuroscience data, and obesity data (amylin asset 295).

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts